Macular Degeneration Treatment Moves Toward Six-Month Refills: Susvimo Wins Support from EU Medicines Committee

For patients with neovascular age-related macular degeneration, preserving vision often means undergoing repeated intraocular injections for many years. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has now issued a positive opinion on Roche’s Susvimo, bringing the EU one step closer to approving the first refillable intraocular implant system of its kind and shifting the treatment focus from “how often to give an injection” to “whether a drug can be delivered steadily and continuously.”

Susvimo is a surgically implanted intraocular drug delivery system that continuously releases the vascular endothelial growth factor inhibitor ranibizumab and is subsequently refilled every 24 weeks. Compared with injections every four weeks, the design substantially reduces the frequency of drug administration into the eye. However, it does not eliminate the need for subsequent care: patients must still return regularly for evaluation, and the procedures must be performed by ophthalmologists trained in vitreoretinal surgery and implantation procedures.

The scope of use recommended by the EMA is quite specific: adults with neovascular age-related macular degeneration whose condition has responded to and become stable following treatment with an intravitreal VEGF inhibitor. In other words, Susvimo is not currently a direct alternative for all newly diagnosed patients. Instead, after a drug’s effectiveness has been confirmed, it offers suitable patients a lower-frequency approach to long-term maintenance.

The Phase 3 randomized comparative study supporting the opinion enrolled a total of 415 patients. According to data disclosed by the EMA and European pharmaceutical media, Susvimo produced results comparable to ranibizumab injections every four weeks in maintaining vision and retinal anatomy. This comparison supports the feasibility of reducing treatment frequency, but the currently available summaries do not provide data on all subgroups, long-term durability, or real-world clinical adherence, so it cannot be assumed that every patient will achieve the same outcome.

Convenience also comes with risks that differ from those of conventional injections. Common adverse reactions listed by the EMA include iritis; a conjunctival filtering bleb or leakage at the implant site; cataract; vitreous opacities or floaters; conjunctival hemorrhage or hyperemia; eye pain; and headache. Because the system must be surgically implanted, clinical decisions cannot be based solely on a comparison of dosing frequency. They must also take into account the condition of the patient’s eyes, surgical risks, and whether the medical institution has the capacity to perform implantation and refills.

The CHMP adopted the positive opinion on July 23, 2026, and the applicant is Roche Registration GmbH. Susvimo was also one of 12 new medicines recommended for approval at that meeting. A positive opinion is not the same as formal EU marketing authorization, and a decision by the European Commission is still pending. If ultimately approved, its actual impact will depend on whether implantation and refill procedures can be safely adopted on a broad scale, and whether the convenience of fewer injections is sufficient to offset the care burden specific to the implant.